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33:1-7.Sequential Bortezomib, Dexamethasone, and
Thalidomide Maintenance Therapy after
Single Autologous Peripheral Stem Cell
Transplantation in Patients with Multiple Myeloma
Firoozeh Sahebi,1,5 Paul H. Frankel,2 Len Farol,1,5 Amrita Y. Krishnan,1 Ji-lian Cai,1,5
George Somlo,1 Sandra H. Thomas,1 Eunicia Reburiano,1
Leslie L. Popplewell,1 Pablo M. Parker,1 Ricardo T. Spielberger,1,5
Neil M. Kogut,1,5 Chatchada Karanes,1 Myo Htut,1 Christopher Ruel,2
Lupe Duarte,2 Joyce L. Murata-Collins,4 Stephen J. Forman1We report feasibility and response results of a phase II study investigating prolonged weekly bortezomib and
dexamethasone followed by thalidomide and dexamethasone as maintenance therapy after single autologous
stem cell transplantation (ASCT) in patients with multiple myeloma. Within 4 to 8 weeks of ASCT, patients
received weekly bortezomib and dexamethasone for six cycles, followed by thalidomide and dexamethasone
for six more cycles. Thalidomide alone was continued until disease progression. Forty-five patients underwent
ASCT. Forty patients started maintenance therapy; of these, 36 patients received four cycles, and 32 completed
six cycles of maintenance bortezomib. Of these 40 patients, nine (22%) were in complete response (CR) before
ASCT, 13 (32%) achieved CR after ASCT but before bortezomib maintenance therapy, and 21 (53%) achieved
CR after bortezomib maintenance therapy. Nine patients not previously in CR (33%) upgraded their response
to CR with bortezomib maintenance. At 1 year post-ASCT, 20 patients achieved CR, and two achieved very
good partial response. Twenty-seven patients experienced peripheral neuropathy during bortezomib therapy,
all grade 1 or 2. Our findings indicate that prolonged sequential weekly bortezomib, dexamethasone, and tha-
lidomide maintenance therapy after single ASCT is feasible and well tolerated. Bortezomib maintenance treat-
ment upgraded post-ASCT CR responses with no severe grade 3/4 peripheral neuropathy.
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Despite recent advances in the treatment of multi-
ple myeloma using novel agents and autologous stem
cell transplantation (ASCT), the disease remains
incurable, with persistent disease as the main cause oftreatment failure. The quality and depth of response
to treatment, particularly the achievement of complete
response (CR) or very good partial response (VGPR),
is associated with significant improvement in
progression-free survival (PFS) and overall survival
(OS) in patients with multiple myeloma [1,2]. In
addition, durability of response is also known to
improve long-term outcome [3].
Consolidation and/or maintenance therapy have
been under investigation for the past 3 decades as
a means of improving response, disease control, and
ultimately survival. Studies using thalidomide, a first-
in-class immunomodulatory drug, either alone or in
combinationwith steroids asmaintenance therapy after
single or double ASCT have consistently reported im-
proved PFS [4-7], supporting the use of post-ASCT
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proteasome inhibitor, in combination with immunom-
odulatory drugs (IMiDs) such as thalidomide or
lenalidomide, and steroids, has shown enhanced
effects on myeloma cytoreduction, based on targeting
complementary, overlapping pathways in myeloma
cell cycle control [8,9]. IMiDs activate capsase-8, en-
hance myeloma cell sensitivity to Fas-induced
apoptosis, and downregulate transcription factor
nuclear factor kappa light chain enhancer of activated
B cells (NF-kB) activity [9]. Alongwith inducing tumor
apoptosis via the NF-kB and Fas/capsase-8 pathways,
bortezomib also stimulates mitochondrial capsase-
9–mediated apoptosis [8,10]. Studies of triple-
combination regimens report CR and near-CR rates
of 30% to 57% in previously untreated patients
[11,12]. However, the combination therapies are
associated with increased toxicity, possibly precluding
the use of these agents for extended periods.
We hypothesized that a sequential post-ASCT
combination maintenance therapy using the protea-
some inhibitor bortezomib and the immunomodulator
thalidomide in combination with dexamethasone
would improve the depth of response, duration of re-
sponse, and tolerability. In 2008, we opened a phase
II study to investigate post-single ASCT maintenance
therapy using weekly bortezomib in combination with
dexamethasone for six cycles, followed by thalidomide
and dexamethasone for six cycles. Thalidomide was
continued until disease progression.MATERIALS AND METHODS
Enrollment and Eligibility
This study was approved by the City ofHope Insti-
tutional Review Board, and all patients provided con-
sent in accordance with the Declaration of Helsinki.
Patients with symptomatic multiple myeloma, aged
#70 years, who were in stage II or III at diagnosis or
progressive stage I requiring chemotherapy and/or ra-
diation therapy (by Durie-Salmon classification) were
eligible for this study. Documentation of disease stag-
ing by both Durie-Salmon classification and the Inter-
national Staging System (ISS) was required. Patients
with nonsecretory myeloma were required to have
measurable serum-free light-chain protein by the
Freelite test (Binding Site Group, Birmingham, UK)
or measurable disease, such as a soft tissue myeloma.
Patients were required to have a minimum number
of mobilized stem cells harvested (4  106 CD341
cells/kg) before enrollment. Adequate organ function
for ASCT was required, based on institutional stan-
dard operating procedures. Patients with grade $2
peripheral neuropathy or progressive disease after
previous induction therapy with bortezomib or thalid-
omide were excluded.Study Design and Treatment
Theprimary objective of this studywas to assess the
feasibility and toxicity of maintenance therapy with se-
quential bortezomib, thalidomide, and dexamethasone
following high-dose melphalan and ASCT in patients
with multiple myeloma. The maintenance therapy
was considered feasible if .70% of the subjects were
able to receive aminimum of four cycles of bortezomib
therapy. Patientswho received bortezomib at a reduced
dose in accordance with the protocol were considered
able to tolerate bortezomib therapy.Maintenance ther-
apy was not considered feasible if\50% of the subjects
were able to tolerate bortezomib therapy. The second-
ary objectives were to assess whether administration of
maintenance therapy with sequential bortezomib, tha-
lidomide, and dexamethasone could improve the CR
rate, 3-year PFS, 3-year OS, or influence the impact
of chromosomal abnormalities on outcome.
Patients were enrolled in this phase II open-label
study after a total 4  106 CD341 cells/kg were mobi-
lized for ASCT. Patients underwent single ASCT us-
ing melphalan 200 mg/m2 and were started on
maintenance therapy within 6 to 8 weeks after trans-
plantation. Patients starting bortezomib therapy were
required to have a WBC count of $3.0 and/or an ab-
solute neutrophil count of .1,000, a platelet count
of $100,000, and no peripheral neuropathy grade
$2 within 14 days before the start of therapy.
Bortezomib was administered i.v. at 1.3 mg/m2 on
days 1, 8, and 15 of a 28-day cycle, in combination
with 40mg of oral dexamethasone on days 1 through 4.
Bortezomib was continued for a total of six cycles in
combination with dexamethasone. This was followed
by maintenance thalidomide starting at 50 mg/day
orally on a 28-day cycle and escalating to a maximum
daily dose of 200 mg, together with dexamethasone
40 mg on days 1 through 4. Dexamethasone was con-
tinued at 40 mg on days 1 through 4 of each 28-day cy-
cle for six more cycles and then stopped. Thalidomide
was continued until the occurrence of disease progres-
sion or unacceptable toxicity. During the thalidomide
phase of the study, all patients received prophylactic
aspirin. Low-molecular-weight heparin or warfarin
was suggested only for patients at high risk for devel-
oping deep venous thrombosis (DVT)/pulmonary em-
bolism, unless contraindicated. All patients received
acyclovir for prophylaxis against varicella zoster for
at least 1 year, in accordance with standard operating
procedure. Bisphosphonates were administered as
clinically indicated.Assessments
Toxicity was assessed using the National Cancer
Institute Common Toxicity Criteria Version 3.
Peripheral neuropathy was assessed at baseline before
ASCT, before the start of bortezomib after ASCT,
Table 1. Patient Characteristics (n 5 45)
Characteristic
Age, years, median (range) 55 (29-70)
Sex, n (%)
Male 25 (56)
Female 20 (44)
Time from diagnosis, months, median (range) 6.3 (3.4-143)
ISS stage, n (%)
I 18 (40)
II 16 (36)
III 8 (18)
Unknown 3 (7)
Durie-Salmon stage, n (%)
I 2 (14)
II 9 (20)
III 34 (76)
Previous treatments included, n (%)*
Thalidomide 15 (33)
Bortezomib 29 (64)
Lenalidomide 10 (22)
b-2 microglobulin 1.8 (1.0-5.3)
Chromosomal abnormalities (at enrollment), n (%)
Hyperdiploidy 4 (9)
Hyperdiploidy + monosomy 13 2 (4)
Chromosome 13 deletions, + other abnormalities 2 (4)
t(4;14) + monosomy 13 1 (2)
t(11;14) 1 (2)
Normal† 35 (88)
*Does not add up to 45 patients, because some patients received more
than one of the listed agents.
†One patient with normal COH targeted FISH results was reported to
have t(4;14) detected by an outside facility before treatment and autol-
ogous transplantation.
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using the Functional Assessment of Cancer Therapy/
Gynecologic Oncology Group’s Neurotoxicity
Questionnaire, Version 4. Response was assessed
based on international uniform response criteria for
multiple myeloma [13] at enrollment before ASCT,
before the start of bortezomib after ASCT, after cycle
six of bortexomib/dexamethasone or at 6 months post-
ASCT, after six cycles of thalidomide/dexamethasone
at 1 year post-ASCT, and yearly thereafter.
Cytogenetics and Targeted Fluorescence In Situ
Hybridization
Bone marrow specimens were examined by con-
ventional cytogenetics. Targeted fluorescence in situ
hybridization (FISH) assays on interphase plasma cells
were performed to detect aneusomy for chromosomes
5, 9, and 15; monosomy or deletion of chromosome
13; aneusomy or deletion of the TP53 gene locus
mapped to chromosome 17; and presence or absence
of the microscopically cryptic t(4;14) fibroblast growth
factor receptor 3 (FGFR3)/immunoglobulin heavy
chain (IGH) fusion gene rearrangement. If gain of
IGH was observed in the FGFR3/IGH assay, then ad-
ditional targeted FISH assays for t(11;14) CCND1/
IGH and t(14;16) IGH/MAF fusion gene rearrange-
ments were performed.
Statistics
The study was powered to determine feasibility,
defined as the ability to tolerate 4 or more months of
bortezomib therapy. A 50% 4-month tolerability rate
was a priori determined to be discouraging, and
a 70% 4-month tolerability rate was considered prom-
ising. With 45 patients, combined with interim moni-
toring, there was 85% power to detect the promising
tolerability rate with a type I error of 10%. Early stop-
ping rules at five, 15, 25, and 35 patients were included
(requiring more than zero, 8, 13, and 19 patients toler-
ating therapy, respectively). There was an 84% chance
of early stopping under the discouraging tolerability
rate. Empirically, interim monitoring success and
more than 25 of 45 patients able to tolerate 4 or
more months of bortezomib therapy were required;
calculations were based on 5,000 simulations. Addi-
tional secondary endpoints, including thalidomide tol-
erability, toxicity, and response are reported.RESULTS
Patient Characteristics
Forty-five patients (25 males and 20 females; me-
dian age, 55 years; age range, 29-70 years) were en-
rolled between March 2008 and June 2010. Patient
characteristics are summarized inTable 1. Themediantime from diagnosis to enrollment was 6.3 months
(range, 3.4-143 months). ISS disease stage at diagnosis
was stage I in 18 patients, stage II in 16 patients,
stage III in eight patients, and unknown in three pa-
tients. Previous treatments before ASCT included
thalidomide/dexamethasone-containing, bortezomib-
containing, and lenalidomide-containing. The median
b-2 microglobulin level was 1.8 g/mL (range, 1.05-5.3
g/mL) at enrollment.
In 10 patients, bone marrow specimens were ab-
normal at enrollment by targeted FISH analyses, but
only one specimen was also abnormal by conventional
cytogenetic analysis. The remaining 35 patients had
normal karyotypes and/or targeted FISH assay at
study enrollment. One patient with a normal targeted
FISH analysis performed at enrollment was reported
by an outside laboratory to have had t(4;14) and a chro-
mosome 13 deletion, detected by FISH at diagnosis
before study enrollment. The 10 patients with cytoge-
netic abnormalities at enrollment are described in
detail in Table 1. Four patient specimens were charac-
terized by numerical gains resulting in hyperdiploidy.
Two specimens were hyperdiploid with concurrent
monosomy 13. Chromosome 13 abnormalities with-
out documented concurrent aneuploidy were observed
in two patients, one patient with near-diploidy with
trisomy 9, concurrent monosomy 13, and loss of an
IGH locus and one patient with a deletion of the
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rearrangement resulting in loss of centromeric se-
quences but retention of both TP53 gene loci. One pa-
tient specimen was characterized by monosomy 13, in
association with a t(4;14) high-risk variant FGFR3/
IGH fusion gene rearrangement. One patient had
a t(11;14) CCND1/IGH fusion gene rearrangement
as the sole anomaly.Table 2. Treatment-Related* Toxicities During Bortezomib
Maintenance Therapy† (n 5 40)
Category/Toxicity Grade 1 Grade 2 Grade 3 Grade 4
Hematologic
Anemia 20 7 0 0
Leukopenia 10 12 1 0
Lymphopenia 2 6 13 0
Neutropenia 8 7 2 0
Thrombocytopenia 12 3 1 0
Nonhematologic
Cataract 0 0 1 0
Diarrhea 3 1 0 0
Dizziness 2 1 0 0
Head and neck edema 2 0 0 0
Limb edema 3 0 0 0
Fatigue 4 1 2 0
Fever 1 0 0 0
Hearing loss 0 1 0 0
Creatinine 1 0 0 0
Upper respiratory infection 1 6 1 0
Bladder infection 0 1 0 0
Insomnia 6 0 0 0
Anxiety 2 1 1 0
Depression 0 1 0 0
Muscle weakness, lower
extremity
1 2 0 0
Muscle weakness, generalized 1 0 0 0
Nausea/vomiting 2 1 0 0
Pain in extremity 2 1 1 0
Sinus bradycardia 0 0 1 0
Weight gain 3 0 0 0
Metabolic
Elevated uric acid 0 1 0 0
Hyperglycemia 7 2 4 0
Hypertriglyceridemia 0 1 0 0
Hypokalemia 3 0 0 0
Hypomagnesium 1 0 0 0
Hypophosphatemia 2 2 2 1
Peripheral neuropathy
During bortezomib 22 5 0 0
Post-ASCT 16 0 0 0
Pre-ASCT 6 0 0 0
*Serious AE attributions listed include those related, likely related, and
possibly related. Not listed are events unlikely related or unrelated to
bortezomib: DVT in one patient with a history of DVT so considered
unrelated, one patient with MI considered unlikely related to bortezo-
mib, and one patient diagnosed with unrelated adrenal carcinoma.
†For comparison, in addition to peripheral neuropathy during bortezo-
mib therapy, previous peripheral neuropathy reported post-ASCT and
pre-ASCT are shown, to demonstrate the progression of peripheral
neuropathy.Feasibility and Tolerability
All 45 enrolled patients underwent ASCT. Five pa-
tients did not start the maintenance phase of the study
because of neurotoxicity (n 5 3), thrombocytopenia
(n 5 1), or withdrawal of consent (n 5 1). Forty
patients started bortezomib maintenance therapy,
and 36 patients received at least four cycles of bortezo-
mib. Four patients discontinued bortezomib mainte-
nance due to toxicity (one myocardial infarction, one
hematologic toxicity, one peripheral neuropathy, and
one for diagnosis of adrenal carcinoma), and four pa-
tients did so due to progressive disease, resulting in
32 patients who completed six cycles of bortezomib/
dexamethasone maintenance therapy. Twenty-five pa-
tients were still receiving therapy at the 1-year assess-
ment (end of the thalidomide and dexamethasone
phase), and 10 patients completed the 2-year assess-
ment. Two patients still on therapy had not yet
reached the 1-year assessment at the time of analysis.
With 32 of the 45 patients (71%) completing 6 months
of bortezomib/dexamethasone maintenance and 36 of
45 (80%) receiving four cycles, the a priori feasibility
condition of .70% of patients able to tolerate
4 months of bortezomib (primary objective) was
achieved.
Fifteen patients required protocol-specified dosage
reductions during bortezomib/dexamethasonemainte-
nance therapy. The median tolerated dose of bortezo-
mibwas 1.3mg/m2 (range, 0-1.3mg/m2). Four patients
(described previously) discontinued bortezomib/dexa-
methasone, nine had a reduced bortezomib dosage, and
two had a reduced dexamethasone dosage.
The median tolerated thalidomide dose was 50
mg/day (range, 0-200 mg/day). The median duration
of thalidomide treatment, estimated by Kaplan-
Meier, was 23.3 months (95% confidence interval
[CI], 9.7-not reached). Only one patient was able to
tolerate thalidomide at 200 mg/day; the remaining
patients could not be escalated to the maximum dose
of 200 mg/day because of toxicity. Five patients
discontinued thalidomide, four due to toxicity and
one due to patient refusal. Of the 32 patients who
started thalidomide therapy, 16 remained on
thalidomide maintenance at the time of analysis,
seven were on hold due to toxicity, and nine had
gone off the study (three for toxicity, five for
progressive disease, and one by patient choice).Toxicities
Thirty-two patients completed the planned six
cycles of bortezomib and dexamethasone. All
treatment-related adverse events (AEs) during bortezo-
mib/dexamethasone treatment cycles are listed in
Table 2.Hematologic grade 3/4AEs occurred in a total
of 17 patients: leukopenia in one, lymphopenia in 13,
neutropenia in two, and thrombocytopenia in one.
Four patients experienced grade 3/4 hyperglycemia.
One patient suffered a grade 3 upper respiratory infec-
tion. There were no reported cases of varicella zoster
infection. One patient experienced myocardial infarc-
tion during the second cycle of bortezomib; attribution
was considered unlikely. One case of DVT occurring
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DVT was considered unrelated. During thalidomide
therapy, up to the 1-year toxicity assessment (done in
25 patients), four patients experienced grade 3 toxicity,
including one patient with a lowWBC count, one with
edema of the lower extremities, one with obstipation,
and one with DVT.
Data on perhipheral neuropathy are presented in
Table 2 based on treatment period, showing increasing
toxicity as treatment progressed. Six patients had grade
1 peripheral neuropathy at enrollment before ASCT.
Of the 40 patients who proceeded to maintenance
therapy, 16 had grade 1 peripheral neuropathy. An ad-
ditional three patients had peripheral neuropathy post-
ASCT that precluded starting maintenance therapy.
After completion of bortezomib therapy, 27 patients
had grade 1 or 2 peripheral neuropathy. No patient ex-
hibited grade 3 or 4 peripheral neuropathy. Of the 25
patients who underwent a 1-year post-ASCT toxicity
assessment, 15 had grade 1 peripheral neuropathy,
and one had grade 2 peripheral neuropathy. Of the
11 patients who reached 2 years post-ASCT, five had
grade 1 peripheral neuropathy, and two had grade 2
peripheral neuropathy.
Response
Themedian follow-up duration for the 45 enrolled
patients was 13.5 months (range, 1.9-34.8 months).
Table 3 summarizes the patient responses at various
stages of therapy. Before ASCT, 10 of the 45 patients
(22%) had CR, 14 (31%) had VGPR, and 21 (47%)
had a partial response (PR). Forty of the 45 enrolled
patients started maintenance therapy with bortezomib
and dexamethasone. After ASCT and before the start
of bortezomib therapy, 13 of these 40 patients
(32.5%) were in CR, 12 (30%) were in VGPR, and
15 (37.5%) were in PR. After bortezomib mainte-
nance, at 6 months post-ASCT, 21 of the 40 patients
(52.5%) achieved CR, seven (17.5%) achieved
VGPR, eight (20%) achieved PR, and four (10%) re-
lapsed. Nine of the 27 patients (33%) not in CR after
ASCT upgraded their response to CR with bortezo-
mib therapy, and one patient in CR after ASCT pro-
gressed during maintenance therapy. An additional
five patients converted to CR during subsequent tha-Table 3. Response in Patients Started on Maintenance Therapy* (n
Response Pre-ASCT Post-ASCT
CR, (%) 9 (22.5) 13 (32.5)
VGPR, n (%) 12 (30) 12 (30)
PR, n (%) 19 (47.5) 15 (37.5)
Relapse, n (%) 0 0
Not assessed, n (%) 0 0
*Five of the 45 patients entered did not proceed tomaintenance; one of these fiv
neuropathy.
†These patients were not assessed because two had not yet reached the 1-ye
adverse effects.lidomide therapy. At 1 year after ASCT and after tha-
lidomide/dexamethasone therapy, 20 of 40 patients
(50%) achieved CR, two (5%) achieved VGPR, three
(7.5%) achieved PR, and six (15%) relapsed with mye-
loma. Nine patients were not assessed at 1 year, two
because they were enrolled for less than 1 year, two be-
cause of withdrawn consent, and five because of with-
drawal due to serious AEs.
Of the 10 patients with abnormal cytogenetic data
at enrollment, only one patient had high-risk t(4;14);
this patient was in CR at the 6-month post-
bortezomib assessment. Of the nine patients with
other cytogenetic abnormalities, response data are
not available for one patient, who never started main-
tenance therapy. For the remaining eight patients, at
the 6-month assessment, there were two patients off-
study, three in CR, one in VGPR, one in PR, and
one who relapsed, and at 1-year post-ASCT, there
were two patients off-study, three in CR, one in
VGPR, one in PR, and one who relapsed. One patient
had previous t(4;14) and chromosome 13 deletion at
diagnosis, detected at an outside facility but normal
FISH findings at enrollment. This patient was in CR
post-ASCT but relapsed during bortezomib therapy.
Progression and Survival
Seven patients suffered relapse or disease progres-
sion (between 2 and 14 months after ASCT), and five
of them died. One other patient died at 18months after
ASCT with no evidence of disease after withdrawing
from treatment upon diagnosis of adrenal carcinoma.
With a median follow-up of 13.5 months, the 1-year
PFS in our series was 88% (95% CI, 0.79%-0.98%),
and the 1-year OS was 95% (95% CI, 0.89%-1.00%).DISCUSSION
Achievement of CR and VGPR remains a powerful
prognostic indicator in patients with multiple mye-
loma. This finding was initially observed with high-
dose therapy and ASCT, given that CR is a rare event
with conventional chemotherapy. More recently,
higher rates of CR have been achieved with the use
of novel therapies with or without ASCT [1,2].5 40)
Post-Bortezomib
at 6 months
Post-Thalidomide
at 1 Year
21 (52.5) 20 (50)
7 (17.5) 2 (5)
8 (20) 3 (7.5)
4 (10) 6 (15)
0 9 (22.5)†
ewas in CR post-ASCT but was unable to proceed because of peripheral
ar point, two withdrew consent, and five withdrew because of serious
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term posttransplantation in an indolent state without
total disappearance of the monoclonal protein,
achievement of CR or VGPR should be a major objec-
tive of new treatment designs in patients with multiple
myeloma.More profound CR states, such as molecular
remission, may be necessary to further improve out-
comes, as recently reported after consolidation therapy
with bortezomib, thalidomide, and dexamethasone in
patients undergoing ASCT [14].
Thalidomide was the first novel agent used alone
or in combination with steroids as consolidation or
maintenance therapy after single or tandem ASCT
for multiple myeloma in an attempt to improve disease
control and has been the subject of six randomized
clinical trials [4-7,15,16]. Significant improvements
in PFS from thalidomide maintenance were observed
in all six of those studies, and significantly increased
OSwas also noted in three of them. Ameta-analysis re-
vealed a trend toward improved OS with maintenance
thalidomide [17]; however, in most reported studies,
the rate of thalidomide discontinuation due to patient
intolerance was inordinately high.
Maintenance therapy after ASCT with newer anti-
myeloma agents, including lenalidomide and bortezo-
mib, is the next logical step in improving the depth
and duration of response. Lenalidomide has been con-
sidered an ideal agent given its efficacy and toxicity pro-
file, along with its oral route of administration.
Preliminary results presented at the 2010 American
Society of Hematology meeting and the 2011 Interna-
tionalMyelomaWorkshop from two randomized stud-
ies using lenalidomidemaintenance therapy after single
ASCT for multiple myeloma showed improved PFS
[18,19]. However, in both studies, similar increased
rates of secondary malignancy were reported with
maintenance lenalidomide therapy. Although the
causal relationship remains to be determined, these
observations emphasize the need to investigate other
active agents, such as bortezomib, in the maintenance
setting.
In 2008, we designed a maintenance study using
sequential bortezomib and thalidomide combined
with dexamethasone in an attempt to take advantage
of the different mechanisms of action and additive ef-
fects of these drugs on myeloma cytoreduction to im-
prove the depth of response. Given concerns about
prolonged bortezomib therapy on a twice-weekly
schedule, we used once-weekly bortezomib dosing
for six cycles, followed by six cycles of thalidomide in
combination with dexamethasone, in an attempt to
minimize the risk of peripheral neuropathy. Our find-
ings suggest that this approach is both feasible and ac-
tive, with a CR rate of .50%. The use of a weekly
bortezomib schedule allows sequential use of thalido-
mide without exacerbation of peripheral neuropathy
beyond grade 1/2. Our data are in agreement with re-cent studies using weekly bortezomib in combination
with alkylating agents and thalidomide in ASCT-
ineligible patients, resulting in a significantly reduced
incidence of peripheral neuropathy with no adverse
impact on response rate or disease control [20,21].
A phase III randomized study by the Nordic group
presented in abstract form reported a significantly
higherCR and near-CR rate of 54% in patients who re-
ceived bortezomib consolidation therapy after single or
tandem ASCT compared with those who received no
consolidation [22]. In the consolidation arm, bortezo-
mib was given twice weekly for the first two cycles,
followed by once-weekly infusion in the subsequent
four cycles. Similarly, the incidence of severe grade
3/4 peripheral neuropathy was relatively low. More re-
cently, a randomized study by the Intergroupe Franco-
phone du Myelome group reported encouraging
results with s.c. bortezomib, which showed similar effi-
cacy and a lower incidence of peripheral neuropathy
compared to i.v. administration [23]. Subcutaneous ad-
ministrationmay provide a more practical and possibly
less neurotoxic delivery of bortezomib, and this route
should be investigated in future studies of consolida-
tion/maintenance therapy.
In summary, our results establish the feasibility of
post-ASCTmaintenance therapy composed of sequen-
tial bortezomib, dexamethasone, and thalidomide.
This regimenwaswell tolerated in our patients, and pe-
ripheral neuropathy was less severe than expected, with
no grade 3 or 4 neuropathies observed. One-third of
the evaluable patients exhibited an increased response
after bortezomib maintenance therapy, and more
than half achieved CR after maintenance therapy. We
acknowledge that our sample size is too small to allow
us to draw definitive conclusions and that larger studies
are needed to establish the impact of bortezomibmain-
tenance on long-term disease control. The feasibility
and impressive CR rate with maintenance bortezomib
therapy provide evidence supporting further investiga-
tion of maintenance bortezomib, paticularly via s.c. ad-
ministration, in combination with other antimyeloma
agents, such as histone deacetylase inhibitors and
next-generation immunomodulatory drugs. Lenalido-
mide could be an attractive option to replace thalido-
mide, having a better response rate and toxicity
profile; however, more data on the risk of secondary
malignancies are required. We are eager to assess the
long-term disease control and survival benefits of com-
bined bortezomib/immunomodulatory maintenance
therapy for multiple myeloma in the future.ACKNOWLEDGMENTS
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